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Introduction
Considering the increasing number of mitochondrial disease genes and the extreme clinical heterogeneity, the strategy to reach a conclusive diagnosis is a complex task for many mitochondrial disorders. There is general awareness that a combination of clinical observations, biochemical evaluation, brain imaging, and muscle biopsies for morphological and functional studies is essential not only to establish a candidate gene approach, but even more in the validation process of causative mutations amongst numerous variants called by next generation sequencing (Wortmann et al., 2015) .
Complex III or ubiquinol:cytochrome c oxidoreductase (E.C. 1.10.2.2; cytochrome bc1 complex) is the central component of the respiratory electron transport chain embedded in the inner membrane of mitochondria in eukaryotes. Mammalian complex III possesses a dimeric structure in which each 'monomer' is composed of 11 different subunits (Schä gger et al., 1986; Iwata et al., 1998) , three of which constitute the catalytic core: MT-CYB (cytochrome b, the only mitochondrial DNA-encoded subunit), CYC1 (cytochrome c1) and UQCRFS1 (Rieske Fe-S protein) (Elstner et al., 2008) . The complex III assembly involves a multi-step process and the formation of different assembly intermediates (Graham et al., 1994; Smith et al., 2012) . The assembly of the complex is completed when UQCRFS1/Rip1 is inserted in the last step, followed by Qcr10 .
Deficiencies in complex III are considered to be relatively rare, but perhaps conditions with isolated complex III defect are only less frequently diagnosed because their detection may be more difficult due to the lack of histological and biochemical hallmarks in skeletal muscle biopsies, e.g. no COX-negative or ragged red fibres (Ferná ndez-Vizarra and Zeviani, 2015) . Complex III deficiencies have most commonly been associated with mutations in the mitochondrial DNA gene encoding cytochrome b. Mutations in nuclear genes encoding structural complex III subunits have been described in the genes coding for subunit 7 (UQCRB, QCR7 in yeast) (Haut et al., 2003) , subunit 6 (UQCRQ, QCR8 in yeast) (Barel et al., 2008) , Core 2 (UQCRC2, QCR2 in yeast) (Miyake et al., 2013) and cytochrome c1 (CYC1, CYT1 in yeast) (Gaignard et al., 2013) . Mutations in genes encoding two human complex III assembly factors, BCS1L (BCS1 in yeast) and TTC19 (no yeast orthologue), have been reported in infants with variable clinical presentation and severity (de Lonlay et al., 2001; De Meirleir et al., 2003; Ghezzi et al., 2011; Nogueira et al., 2013) . The molecular defect in most complex III-deficient individuals remains to be identified, suggesting that additional assembly factors with deleterious mutations remain to be discovered.
Recently one paper reported a mutation in LYRM7 (Mzm1 in yeast) (Invernizzi et al., 2013) , a homozygous substitution (c.73G4A), predicting a drastic change in a highly conserved amino acid residue (p.D25N) (Invernizzi et al., 2013) ; the mzm1 deleted yeast strain expressing the mzm1 D25N mutant allele showed temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the UQCRFS1/Riske Fe-S protein, and reduced complex III activity and amount (Invernizzi et al., 2013) .
Since its introduction into medicine, MRI has emerged as a valuable tool for the differential diagnosis of leukoencephalopathies, including mitochondrial encephalomyopathies (Van der Knaap and Valk, 2005) . Several examples of how MRI pattern recognition was central in the identification of novel disorders and mitochondrial defects include leukoencephalopathy with brainstem and spinal cord involvement with elevated lactate (LBSL) caused by mutations in DARS2 encoding mitochondrial aspartyltRNA synthetase, (Scheper et al., 2007) ; leukoencephalopathy with thalamus and brainstem involvement with elevated lactate (LTBBL) caused by mutations in EARS2, the gene encoding mitochondrial glutamyl-tRNA synthetase (Steenweg et al., 2012) ; the leukoencephalopathy caused by mutations in NUBPL, encoding an iron-sulphur cluster assembly factor for complex † (Kevelam et al., 2013) ; and the leukoencephalopathy caused by mutations in APOPT1, encoding a mitochondrial protein that seems to connect apoptosis with increased reactive oxygen species production (Melchionda et al., 2014) . In most mitochondrial leukoencephalopathies, white matter and, to a lesser degree, grey matter structures are affected with a peculiar distribution that has enabled recognition of specific genetic forms with or even without the integration of a specific defect in the mitochondrial respiratory chain enzymes (Scheper et al., 2007; Steenweg et al., 2012) .
In the present study we describe five novel mutations in LYRM7 found in five unrelated subjects, and an already described LYRM7 mutation (Invernizzi et al. 2013) in two siblings. All patients were characterized by a similar and distinct MRI pattern of a progressive leukoencephalopathy with numerous small cavitations in the periventricular and deep cerebral white matter; most of them showed a severe complex III defect.
Materials and methods

Standard protocol approvals, registrations, and patient consent
The study was approved by the Ethical Committees of the Children Hospital Bambino Gesù , Rome, Italy, the Neurological Institute Besta, Milan, Italy, and the VU University Medical Center, Amsterdam, The Netherlands, in agreement with the Declaration of Helsinki. Informed consent was signed by the parents of the patients.
Patients
Patients 1, 2, 3 and 4 were included in a targeted resequencing study performed in 23 patients displaying biochemical defects in mitochondrial respiratory chain complex III. Based on the MRI documented in Patient 1, we selected from the Amsterdam and Washington databases, which together contain more than 4000 cases with an unclassified leukoencephalopathy, three additional patients (Patients 5, 6 and 7) with a typical neuroimaging pattern, together with two additional patients that were considered to have an atypical distribution of lesions. The MRIs of all patients were systematically analysed as previously described (van der Knaap et al., 1999) and clinical histories and laboratory findings were reviewed.
Molecular studies
Genomic DNA was extracted by standard methods from leucocytes. For Patient 1, targeted resequencing was performed at the BGI-Shenzhen (BGI-Shenzhen, Shenzhen, China). A custom probe library was used for targeted resequencing (Agilent SureSelectXT Custom Kit) designed to capture coding exons and flanking intronic stretches (20 nt) of 1381 genes known to be functionally related to mitochondrial disorders ('Mitoexome', Calvo et al., 2012) , followed by deep sequencing using Illumina HiSeq technology, providing 255 Â effective mean depth. For Patients 2 and 4, a customized gene panel (TruSeq Custom Amplicon, Illumina) containing 72 genes previously associated with mitochondrial disorders and isolated mitochondrial respiratory chain complex deficiency ('Mitoiso' panel; details available upon request) was used for library preparation; then samples were analysed by a MiSeq system (Illumina), with 100Â effective mean depth. Sanger sequencing was used to validate the parallel sequencing data, as well as to check variant segregation in families.
To assess the functional effect of splice-site variants, polyA + RNA was purified from cultured skin fibroblasts and reverse-transcribed to cDNA using the First Strand cDNA Synthesis kit (Roche Diagnostics).
Functional studies Human samples
Protein studies: For structural studies fibroblasts were processed as described elsewhere (Nijtmans et al., 2002) . Briefly, mitochondrial membranes were isolated from 2.6 Â 10 6 cells.
Pellets were suspended in phosphate-buffered saline and solubilized for 10 min with digitonin (2 mg/mg protein), followed by 1% (v/v) lauryl maltoside (Sigma Aldrich). Proteins (35-80 mg) were separated by first dimensional blue native gel electrophoresis (BNGE) in a linear 5-13% gradient nondenaturing gel; thereafter, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane and subjected to western blotting. For electrophoresis in sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE), 30 mg of fibroblast mitochondria were loaded in a 12% denaturing gel. For immunoblot analysis, PVDF membranes were probed with monoclonal antibodies and reactive bands were detected using LiteAblot Õ Extend Long Lasting Chemiluminescent Substrate (Euroclone). Densitometry analysis was performed using Quantity One software (Bio-Rad).
Antibodies: Complex I -39 kDa subunit (NDUFA9); complex II -70 kDa (SDHA); complex III -UQCRC1 (Core protein 1), -UQCRC2 (Core protein 2) and -UQCRFS1 (Rieske Fe-S protein) subunits; complex IV -subunit II (COXII); complex V -subunit alpha (ATP5A1), and porin (VDAC) were purchased from MitoSciences (Eugene). LYRM7 antibody was purchased from Abcam.
Yeast experiments
Strains, media and miscellaneous yeast procedures: Yeast strains were BY4741 (MATa; his3Á1; leu2Á0; met15Á0; ura3Á0) and its isogenic mzm1:KanMX4 null mutant (Euroscarf collection). Strains were grown in synthetic complete (SC) defined medium (6.9 g/l YNB) without amino acids (ForMedium) supplemented with 1 g/l dropout mix without uracil (Baruffini et al, 2010) . Carbon sources (Carlo Erba Reagents) were added as indicated in the text in liquid phase or after solidification with 20 g/l agar (ForMedium). Transformation of Saccharomyces cerevisiae has previously been described (Schiestl and Gietz, 1989) .
Construction of yeast mutant alleles and DNA manipulation: Plasmid pFL38 harbouring wild-type MZM1 allele has been previously described (Invernizzi et al, 2013) . The pFL38-MZM1 construct was used as a template to introduce stop codon at positions Q70 or L64 duplication by PCR-based site directed mutagenesis, using the primers listed in Supplementary Table 1. All constructs were verified by Sanger sequencing.
Respiration measurement and respiratory chain complex activities: Oxygen consumption rate was measured at 30 C from yeast cells cultured for 18 h at 28 C in SC medium supplemented with glucose at non-repressing concentration of 0.6% using a Clark-type oxygen electrode (Oxygraph System Hansatech Instruments) with 1 ml of air-saturated respiration buffer (0.1 M phthalate-KOH, pH 5.0), 10 mM glucose. The reaction started by addition of 20 mg of wet-weight cells, as described (Goffrini et al, 2009) . NADH-cytochrome c oxidoreductase activity (NCCR) and complex IV specific activities were measured spectrophotometrically on a mitochondrial-enriched fraction prepared as previously described Soto et al., 2009 ) after a cellular growth to a concentration of 1.5-2 OD 600 in SC medium supplemented with 2% galactose and 0.2% glucose.
Mitochondrial protein purification and SDS-PAGE
Mitochondria were purified as previously reported (Goffrini et al., 2009) . Protein concentration was quantified according to Bradford (Bio-Rad). Mitochondrial proteins (15 mg) were separated by 12% SDS-PAGE, and electro-blotted onto nitrocellulose filters that were then incubated with anti-Rip1 antibodies (a generous gift from Prof. Alexander Tzagoloff) and porin (Abcam Mitoscience). ECL Western Blotting Substrate (Thermo Scientific Pierce) was used for final detection.
Results
Clinical and laboratory findings
The clinical details of the patients in whom we found mutations in LYRM7 are reported in Supplementary Table 2. A clinical report on Patient 1 is provided here followed by a summary report on the remaining patients to highlight the common clinical features.
Patient 1 is a male born at term from parents that denied consanguinity. Mild developmental delay was noted at 8 months of age because he was not able to sit without support. At age 11 months he was admitted to hospital for psychomotor regression, marked hypotonia and failure to thrive. Neurological examination revealed facial weakness, swallowing difficulties, axial hypotonia with spastic hypertonia of arms and legs, and bilateral pes equinus. Plasma lactate acid was increased to 3.73 mmol/l (normal values: 0.444-2.22 mmol/l), and no organic aciduria was detected. During the hospitalization percutaneous endoscopic gastrostomy became necessary. At follow-up, the clinical course was characterized by multiple episodes of vomiting and metabolic acidosis provoked by infectious illnesses and requiring hospitalization. These episodes led to psychomotor regression. Treatment with intravenous dexamethasone (10 mg/kg/d) resulted in some clinical improvement. Neurological examination at age 3 years showed severe psychomotor delay; language was limited to $20 words. The child had axial hypotonia, severe spastic-dystonic tetraparesis of the limbs and marked kyphoscoliosis. At age 3 years and 8 months, a sudden deterioration of the clinical picture occurred with prolonged apnoea and cardiocirculatory arrest that required tracheostomy. Cardiac involvement was excluded whereas liver ultrasound displayed increased volume with irregular structure. Transaminases and creatine kinase were always in the normal range. Visual-evoked and brainstem auditory potentials were abnormal. Of note, he presented with recurrent episodes of VII cranial nerve paralysis, improving on dexamethasone treatment. The latest neurological examination at 7.5 years showed severe psychomotor delay, ophthalmoplegia, nystagmus, facial weakness and spastic-dystonic tetraparesis. Muscle and skin biopsy were performed at 18 months. The spectrophotometric determination of mitochondrial respiratory chain complex activities displayed an isolated 75% reduction of complex III normalized to citrate synthase (complex III/CS) in muscle biopsy.
Of the remaining six subjects from five families, two were sibs (Patients 3 and 4). The other four patients (Patients 2, 5, 6 and 7) were sporadic, but two of them (Patients 2 and 7) originated from inbred families. Most patients manifested with a mild delay of motor milestones. Three of six patients presented with an episode of subacute encephalopathy characterized by psychomotor regression, often irritability, and sometimes stupor or coma, within the first 2 years of life. One patient presented with such an episode at the age of 6 years, and one at 14 years, although both patients already displayed developmental delays and mild motor dysfunction. One of the sibling patients is still asymptomatic at age 6 years. These episodes were recurrent in most patients and were accompanied by lactic acidosis. They were typically induced by febrile illnesses, but sometimes without any relevant antecedent. Most patients displayed failure to thrive and recurrent vomiting; many were eventually tube-fed. Following a period of a few years all affected children were severely disabled and one died at 7 years.
The laboratory results of the patients are summarized in Supplementary Table 3 . Metabolic studies only revealed increased lactic acid in body fluids. The biochemical analysis of mitochondrial respiratory chain in muscle biopsy, when available, consistently showed a marked defect of complex III.
MRI abnormalities
The details of the MRI findings are provided in Supplementary Table 4 . MRIs of Patient 1 are described in detail here, followed by a summary of the MRI findings in the other patients.
In Patient 1 the first MRI [ Fig. 1A (a-h)] performed at age 19 months showed extensive, inhomogeneous, partially multifocal and partially confluent signal abnormalities in the periventricular and deep cerebral white matter, relatively sparing the directly subcortical white matter. Fluidattenuated inversion recovery (FLAIR) images showed numerous isolated cavitations within the abnormal white matter, surrounded by a rim of solid tissue [ Fig. 1A(e  and f) ]. The corpus callosum was abnormal in signal and contained multiple cavitations [ Fig. 1A(b and f) ]. Signal abnormalities without cavitations were present in the posterior limb of the internal capsule and central tegmental tracts in the brainstem. Signal abnormalities with cavitations were present in the border between medulla oblongata and cervical spinal cord [ Fig. 1A(b and h) ]. Diffusion restriction with low apparent diffusion coefiicient (ADC) values was observed in the non-cavitated abnormal white matter [ Fig. 1A(c and d) ]. No enhancement after contrast was present. The second MRI [ Fig. 1A(i-p) ] performed at age 3.5 years displayed an increase in the extent of the cerebral white matter abnormalities, including the corpus callosum, containing high numbers of small, roundish cysts. The middle cerebellar peduncles and cerebellar white matter were also affected, right more than left, as well as the cervicomedullary junction [ Fig. 1A(k and l) ]. Again, diffusion restriction with low ADC values was observed in the non-cavitated abnormal white matter [ Fig. 1A(o and p) ].
The other MRIs confirmed such a pattern (Fig. 1B) . The candidate gene approach of selecting the MRI from undiagnosed patients from the Amsterdam and Washington databases designated five patients who showed an MRI pattern of cavitating leukodystrophy, although only three patients with bialellic mutations in LYRM7 were the ones considered to have a typical distribution of lesions. In the other two patients the cystic cerebral white matter lesions remained more limited in extent without signal abnormalities outside the cysts (one patient) or largely confined to the parieto-occipital region (the other patient). This result confirmed the rarity of LYRM7-related cavitating leukodystrophy in a large cohort of patients with unclassified leukodystrophies and the diagnostic value of MRI for this genetic disorder. Early MRIs in the patients with LYRM7 mutations showed limited, multifocal or more confluent signal abnormalities involving the periventricular and deep cerebral white matter, already containing small cysts in the earliest stages [ Fig. 1B(a and b) ]. Over time the abnormalities became more extensive [ Fig. 1B(c-f) ]. The corpus callosum was often, but not invariably involved in the process. The middle cerebellar peduncles, high cervical spinal cord and the cervicomedullary junction were frequently affected [ Fig. 1B(g and h) ]. In one patient, cystic degeneration of the cervical spinal cord occurred. Diffusion restriction was typically present, either diffuse or multifocal, often especially in the rim of cysts. Contrast enhancement was variable, if present typically in the rim of cysts [ Fig. 1B(i-l) ]. Interestingly the MRI pattern of the asymptomatic Patient 4 showed similar typical abnormalities [ Fig. 1B(a and b) ].
Targeted resequencing and Sanger validation
The details of the mutations identified are provided in Supplementary Table 3 . Parallel targeted resequencing of the Mitoexome (Calvo et al., 2012) on Patient 1 and of the Mitoiso gene panel on Patients 2 and 4 were performed, respectively. After excluding previously annotated single nucleotide changes occurring with high frequency in populations (frequency 40.1%), we prioritized the retained changes identified in each gene according to the presence of homozygous or compound heterozygous variants with functional impact (i.e. non-synonymous variants and changes affecting splice sites), as expected for a recessive inherited trait. In Patient 1, this filtering led to the identification of a single gene entry, LYRM7 (NC_000005.10, NM_181705.3), in which a homozygous mutation was recognized (c.244 + 5insG) ( Fig. 2A and B) . Polyemrase chain reaction (PCR) and sequencing analysis of cDNA obtained from Patient 1 revealed skipping of exon 4 ( Fig.  2C and D) resulting in a frameshift and predicting the synthesis of a truncated protein (p.K82Nfs*10), confirming the deleterious effect of the intronic variant c.244 + 5insG on the splicing process of LYRM7 transcript. Similarly, a single homozygous variant in LYRM7 remained after the filtering procedure in Patients 2 and 4: a trinucleotide duplication c.193_195dup (p.L66dup) was identified in the former (Fig. 2E ), and the previously described c.73G4A missense change (p.D25N) in the latter (Fig. 2F) . Sanger sequencing confirmed the presence of mutations in both patients ( Fig. 2E and F) , and cosegregation with the disorder; moreover the c.73G4A change was homozygous in Patient 3, who was the brother of Patient 4, and heterozygous in their parents (Fig. 2G) .
Sanger sequencing of the entire coding sequence of LYRM7 and intron-exon boundaries was performed in three additional patients. Patient 5 was found homozygous for the c.243_244 + 2del, which is predicted to dramatically affect recognition of the splice donor motif of exon 4 and likely impair proper RNA splicing ( Fig. 2H and I ), while Patients 6 and 7 were found to be homozygous for the c. 214C4T (p.Q72*) (Fig.  2L) , and c.37delA (p.T13Hfs*17) (Fig. 2M) At the age of 2.5 years, the MRI of Patient 4, clinically asymptomatic, shows starting multifocal abnormalities in the periventricularwhite matter with small cysts (a and b). At age 14 years, the MRI of Patient 6 shows extensive signal abnormalities in the periventricular and deep cerebral white matter with numerous small cysts (c and d). The cysts in Patient 7 are larger (age 3 years; e and f). In Patient 2, a small lesion is seen at the cervicomedullary junction (1.8 years; g), while a much larger lesion is seen extending into the cervicospinal cord in Patient 6 (age 14; h). In Patient 5, enhancement of the rim of the sesions is seen (10 years; i and j), whereas small multifocal enhancing spots are seen in Patient 3 (6 years; k and l). and show reduction of complex III activity. In Patient 6 a muscle sample was not available; in Patient 7 the enzyme activity of complex III was initially not measured and by the time biallelic mutations in LYRM7 were found, no residual muscle sample was available for western blotting and spectrophotometric analysis. In samples from Patient 1's fibroblasts, BNGE displayed a severe reduction of the entire complex III complex associated to a compensatory increase of complex I (Fig. 3A and B) . SDS-denaturing gel displayed a dramatic reduction of LYRM7, as expected for the frameshift predicted by cDNA analysis, associated with a partial reduction of UQCRFS1 (Fig. 3C and D) . Two (Ct) and Patient 1 (Pt.1) was subjected to western blotting. Antibodies against the UQCRC2 subunit revealed a severe reduction of complex III (CIII), whereas an increased amount of complex I (CI) and V (CV) was evident using antibodies against NDUFA9 and ATPase (ATP5A1) subunits, respectively. The signal of complex II (CII) SDHA subunit was used as a control for equal loading and for normalization in the densitometry analysis. The relative intensities are reported in B. The same samples were separated by denaturing SDS-PAGE; specific antibodies against complex III (UQCRC1, UQCRC2, UQCRFS1, and LYRM7), reported in C, and specific antibodies against complex II (SDHA), complex V (ATP5A1), complex I (NDUFA9), and complex IV (COXII), reported in E, were used for immunodetection. The mitochondrial protein porin (VDAC) was used as a control for equal loading and for normalization in the densitometry analysis. The relative intensities are reported in D and F, respectively. The quantity of LYRM7 was found to be severely affected, as well the UQCRFS1 subunit.
additional subunits of complex III (UQCRC1 and UQCRC2) were normally expressed, as well as subunits that are part of other mitochondrial respiratory chain complexes ( Fig. 3E and F) . A strong decrease of LYRM7 amount was observed also in fibroblasts from Patient 2 and in skeletal muscle from Patients 3 and 4 ( Supplementary Fig. 1 ), despite the latter subjects carrying a missense mutation whereas Patient 2 harboured a trinucleotide duplication causing the introduction of an extra amino acid in the protein.
Yeast
To validate the pathogenicity of the mutations p.Q72* (found in Patient 6) and p.L66dup (found in Patient 2) we used the yeast S. cerevisiae as a model system taking advantage of the presence of the orthologous gene MZM1. We first introduced the changes equivalent to the human mutations into the yeast MZM1 wild-type gene cloned in a centromeric monocopy vector. The human Q72* and L66dup mutations correspond to yeast Q70* and L64dup, respectively. The MZM1, mzm1 Q70* and mzm1 L64dup constructs were used to transform the mzm1Á null mutant, giving rise to mzm1Á/MZM1, mzm1Á/mzm1 Q70* and mzm1Á/mzm1 L64dup yeast strains. The mzm1Á strain was transformed also with the empty vector as a negative control.
To detect a possible respiratory growth defect, equal amounts of serial dilutions of cells from exponentially grown cultures were spotted onto SC plates supplemented with either 2% glucose or 2% ethanol. The growth was scored after 3 days of incubation at 28 C or 37 C. A clear growth defect of the mzm1Á/mzm1 Q70X and mzm1Á/ mzm1
L64dup was observed in ethanol-containing plates incubated at 28 C and a complete growth inhibition at 37 C (Fig. 4A) , similar to the mzm1Á mutant (Atkinson et al., 2010; Invernizzi et al., 2013) .
To better define the oxidative growth deficiency, we measured oxygen consumption, NCCR and COX activity and cytochromes spectra. The O 2 consumption rates of mzm1Á/mzm1 Q70* and mzm1Á/mzm1
L64dup were $60% less than that of mzm1Á/MZM1 and similar to that displayed by mzm1Á (Fig. 4B) . In both mutant strains as well as in the null strain mzm1Á biochemical assays showed a severe and specific decrease of complex III activity (40-50% residual activity) whereas complex IV (cIV, cytochrome c oxidase, COX) activity was normal (Fig. 4C) . In addition both mutants, mzm1Á/mzm1 Q70* mzm1Á/mzm1 L64dup exhibited a significant reduction of the peak at 560 nm, corresponding to respiratory cyt b (not shown). These results are consistent with the respiratory growth defect observed in the mutant strains mzm1Á/mzm1 Q70* and mzm1Á/ mzm1
L64dup and paralleled the reduction of respiratory activity.
Cells lacking Mzm1 have impaired complex III activity due to attenuated levels of the Rieske iron-sulphur protein, (Rip1p in yeast) insertion. To evaluate the effects of the mzm1 Q70X and mzm1 L64dup mutations on Rip1p biogenesis and complex III function, we studied mitochondria purified from mzm1Á/MZM1, mzm1Á/mzm1 Q70* mzm1Á/ mzm1
L64dup and mzm1Á strains, cultured at 28 C in SC medium. Mitochondrial proteins were resolved by SDS-PAGE and immune-visualized by western blot analysis. As shown in Fig. 4D , the Rip1 level was greatly reduced in mzm1 Q70* and mzm1 L64dup mutants that behaved as the null mutant mzm1Á (Cui et al., 2012) . These data support the pathogenic role of their human counterpart.
Discussion
MRI is a sensitive tool to diagnose leukoencephalopathies. It is also of great help in distinguishing different individual disorders within the large group of all leukoencephalopathies by distinct patterns of abnormalities. In recent years it has been shown multiple times that this MRI-based approach also works very well for mitochondrial leukoencephalopathies. Consistent and striking patterns of abnormalities could be linked to specific mitochondrial dysfunctions and gene defects, facilitating the differential diagnosis of mitochondrial leukoencephalopathies and allowing molecular screening to be limited to a subset of genetic defects, either known or unknown, that affect different functions of mitochondria. The often striking MRI patterns may even allow the identification of the causative genes using the brain imaging and omitting the biochemical data (Morato et al., 2014) .
In 2013, a homozygous mutation in LYRM7 was described by candidate gene approach in a single individual to be associated with early onset, fatal severe encephalopathy, lactic acidosis and profound, isolated complex III deficiency in skeletal muscle (Invernizzi et al., 2013) . The brain MRI of this patient showed a leukoencephalopathy. However, the pattern of distribution and progression of the white matter lesions associated with LYRM7 mutations were not outlined. In the present study, we extended that initial observation by providing evidence that LYRM7 mutations recur in cases with leukoencephalopathy associated with a biochemical defect of mitochondrial respiratory chain complex III, and reporting a more complete assessment of the phenotypic variation associated with these molecular lesions.
By targeted resequencing on a cohort of patients with mitochondrial respiratory chain complex III deficiency, we were able to identify homozygosity for LYRM7 mutations in three unrelated families. Three additional patients were selected for mutation analysis in the same gene on the basis of the distinctive brain MRI, indicating that the radiological phenotype associated with mutations in LYRM7 is distinctive. On the other hand, our failure in identifying LYRM7 mutations in complex III-deficient patients with different MRI patterns suggests that the MRI phenotype associated with LYRM7 mutations is relatively homogeneous. The characteristic MRI profile consists of essentially multifocal white matter abnormalities in the periventricular and deep cerebral white matter, coalescing to more confluent abnormalities. The focal lesions were rarefied and cystic, resulting in a peculiar row of small cystic lesions around the ventricles. The corpus callosum was variably affected. The cerebral cortex and central grey matter nuclei were consistently spared. Frequently diffusion restriction was seen in the abnormal white matter, especially in the rims of the small cystic lesions. Proton magnetic resonance spectroscopy was performed in three patients and showed elevated lactate in two. Within the posterior fossa, mainly the middle cerebellar peduncles could be involved. Cervical spinal cord signal abnormalities were seen in most patients. Follow-up MRIs were available for two patients (Patients 1 and 5) and showed an increase in extent of the cerebral and spinal cord abnormalities. Among the analysed subjects with complex III deficiency and without LYRM7 mutations, none had the same clinical and radiological presentation as the LYRM7-positive patients and the few individuals with leukoencephalopathy showed only slight white matter changes without cavitations. Interestingly it should be noted that such typical MRI abnormalities were identified in an asymptomatic 6-year-old girl whose elder sibling showed early onset manifestations of delayed motor milestones and psychomotor regression at age 6 years following a febrile illness, which emphasizes the occurrence of clinical heterogeneity. Functional studies in human samples (Patients 1-4) and yeast mutagenesis experiments (for mutations found in Patients 2 and 6) confirmed mutations pathogenicity and their link with impaired complex III. All the identified LYRM7 mutations, irrespective of their type (nonsense, missense, frameshift, and splice-site) were associated with a strong decrease in protein level. Measurement of mitochondrial respiratory chain activities in available muscle biopsies displayed a specific complex III defect. Immunoblot analyses showed reduced amount of the holocomplex and supported the hypothesized role of LYRM7 on the last step of the complex III assembly; in fact, despite the normal amount of UQCRC1 and UQCRC2, which are components of the pre-complex III 2 intermediate, a dramatic reduction was evident for UQCRFS1, which is part of the mature complex III. In yeast cells expressing mzm1 Q70* or mzm1 L64dup mutant alleles, the oxidative growth, the oxygen consumption rate, NCCR-specific activity and Rip1 amount were markedly reduced and were comparable to values obtained in the mzm1Á null mutant. These results indicate that both yeast alleles expressing p.Q70* and p.L64dup changes behave as null alleles, suggesting the pathogenicity of the corresponding human Q72* and L66dup mutations.
Mzm1 in yeast, and possibly LYRM7 in humans (Sá nchez et al. 2013), plays a role in the last steps of complex III assembly, being involved in the maturation of UQCRFS1/Rip1, an essential catalytic subunit of complex III (Atkinson et al., 2011; Cui et al., 2012) . Overexpression of epitope-tagged human LYRM7 resulted in elevated UQCRFS1 in the mitochondrial soluble fraction and impaired the assembly of mature complex III, while downregulation of LYRM7 caused a decrease in the amount of UQCRFS1 (Ferná ndez-Vizarra and Zeviani, 2015); moreover, co-immunoprecipitation assays revealed that LYRM7 and UQCRFS1 interacted in a low molecular mass intermediate (Sá nchez et al. 2013) . Thus, the proposed function of LYRM7 was to bind and stabilize UQCRFS1 in the mitochondrial matrix prior to the incorporation of UQCRFS1 into complex III in the inner mitochondrial membrane by BCS1L.
Differently from what is known for BCS1L and TTC19, whose causative mutations have recurrently been reported (Ardissone et al., 2015; Koch et al., 2015; Ferná ndezVizarra and Zeviani, 2015) , only one mutation has previously been described in LYRM7 (Invernizzi et al., 2013) , suggesting a minor impact of dysregulated function of this protein in human disease. By reporting five novel unrelated cases with biallelic LYRM7 mutations, we document a more important contribution of LYRM7 lesions as a cause of complex III deficiency. Our findings confirm previous observations indicating the requirement of LYRM7 for proper complex III assembly, possibly functioning as a soluble mitochondrial matrix chaperone for UQCRFS1, the last catalytic subunit to be incorporated into the holocomplex (Sá nchez et al., 2013) .
